Aelin Therapeutics is a privately held Belgian biotechnology company, pioneering a novel modality in drug development. Using our Pept-in platform technology, we can create a completely new class of antibiotics and first-in-class therapeutics against high-value undruggable human targets. The technology harnesses the power of protein aggregation to specifically induce functional knockdown of a target protein.